Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s closure of the period quarter ended 2016-12-31 had EPS estimate of $0.21.

The reporting of EPS estimates seven days ago were $0.21 while that of 30 days were at $0.21. EPS estimates reported 60 days ago were $0.21. 90 days had $0.21. From 7 days ago had 0% as the percentage change in EPS estimates.

EPS revisions up were at 0 in the last 7 days. The EPS revisions down during the same period were 0. 30 and 60 days had 0 and 2, as the number of up revisions of EPS. 90 and 120 days had 2 and 2 as the number of up revisions of EPS.

Down revisions of EPS in the last 30 and 60 had a respective match of 0 and 3. 90 days had 3 while that of 120 days were at 3.

The lower period of the last 18 days had number of EPS revisions up at 1 but the EPS revisions down were at 4.

Earnings Surprises

The actual earnings for the period ended 2, which was the mean EPS estimate immediately prior to the announcement is $0.21. The actual EPS as per the 2016-08-02 announcement was $0.18. $0.05 is the EPS surprise amount in per share dollar but it was 38.46% in percentage terms. Immediately prior to the announcement of actual earnings, the standard deviation of all EPS estimates is $0.02.

Quarterly Sales Estimates

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s arithmetic mean of all Annual sales estimation is $58.922. The median of all Annual sales estimates is $58.655. The calculation of the fiscal year’s 2016 estimate was by 4 analysts for this company. The respective measures of the highest and the lowest annual estimates are $60.97 and $57.41. The yardstick deviation of all Annual sales estimates is $1.529.

There is an increment in the number of analysts covering the stock and who have also increased their sales estimate to 4 over the past week. The same has happened to those who have decreased their sales estimate over the same period to 4. The mean estimate from past week’s percentage change is 0%.

The increase and decrease of the sales estimate from the number of analysts covering the stock since one month ago are at a respective rate of 4 and 4, with the percentage change of the mean approximation from one month ago being 0%.

The period of three month ago had 4 and 4 respectively increase and decrease their sales estimate, with the number of analysts covering the stock but -1.616% was the three month’s percentage change of the mean estimate.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...